Hepatitis C Virus Infection Screening Guidelines

Initial Screening Approach

The American Association for the Study of Liver Diseases recommends HCV-antibody testing with reflex HCV RNA polymerase chain reaction testing as the initial screening test for hepatitis C infection in adults 1, 2, 3
The initial screening strategy for HCV follows a two-step process: Step 1 involves HCV-antibody testing using an FDA-approved assay, and Step 2 involves reflex HCV RNA PCR testing to confirm active infection 1, 3
Reflex testing approach requires only a single blood collection, eliminating the need for a return visit for confirmatory testing, and addresses a major barrier in the HCV care continuum 3, 4, 5

Special Testing Considerations

For individuals with recent exposure (within 6 months), HCV RNA testing or follow-up HCV-antibody testing ≥6 months after exposure is recommended for those with negative antibody tests, as per the Centers for Disease Control and Prevention guidelines 2, 3
The American Association for the Study of Liver Diseases suggests considering direct HCV RNA testing for immunocompromised patients, as antibody production may be delayed or inadequate 5
For patients at risk for reinfection, HCV RNA testing is recommended since antibody tests will remain positive after prior clearance, according to the American Association for the Study of Liver Diseases 3, 5
Dried blood spot collection can be used for sequential antibody and reflex RNA testing in rural or difficult-to-access populations, requiring only a fingerstick rather than venipuncture, as recommended by the World Health Organization 4, 5

Test Interpretation

A positive antibody test with positive RNA indicates current (active) HCV infection, requiring evaluation for treatment, as stated by the American Association for the Study of Liver Diseases 3
A positive antibody test with negative RNA suggests past resolved infection or false positive, and patients should be informed they do not have current infection but are not protected from reinfection, according to the Centers for Disease Control and Prevention 6, 5
A negative antibody test indicates no evidence of current or past infection, unless recent exposure or immunocompromised, as per the American Association for the Study of Liver Diseases 5

Who Should Be Screened

The American College of Physicians recommends universal screening with one-time HCV screening for all adults aged 18-79 years, with a strength of evidence rated as high 7, 8
Risk-based screening is recommended for persons <18 years with risk factors, such as those with a history of injection drug use, as stated by the American Academy of Pediatrics 1, 3
Periodic testing is recommended for those with ongoing risk factors, with frequency determined by individual risk assessment, according to the Centers for Disease Control and Prevention 1, 3
Annual testing is specifically recommended for people who inject drugs and men with HIV who have unprotected sex with men, as per the American Association for the Study of Liver Diseases 1, 8

Additional Testing After Diagnosis

Quantitative HCV RNA testing is recommended prior to antiviral therapy to establish baseline viral load, with a strength of evidence rated as moderate, according to the American Association for the Study of Liver Diseases 3, 5
HCV genotype testing may be considered when it would alter treatment recommendations, though becoming less necessary with pangenotypic direct-acting antiviral regimens, as stated by the European Association for the Study of the Liver 3, 5

Common Pitfalls to Avoid

Relying solely on antibody testing can miss active infection or incorrectly classify resolved infections as current, with a strength of evidence rated as high, according to the American Association for the Study of Liver Diseases 3, 5
Missing the diagnosis in high-risk groups, especially in people who inject drugs or immunocompromised patients, can have significant consequences, as stated by the Centers for Disease Control and Prevention 8
Delayed diagnosis due to failure to implement reflex RNA testing can lead to patients being lost to follow-up between antibody and confirmatory testing, with a strength of evidence rated as moderate, according to the American Association for the Study of Liver Diseases 4, 5
Overlooking reinfection using only antibody testing in previously infected patients will miss reinfection, as per the American Association for the Study of Liver Diseases 3, 5

Hepatitis C Screening Recommendations

Primary Recommendation

The U.S. Preventive Services Task Force recommends that all adults aged 18-79 years should receive universal, one-time screening for hepatitis C virus (HCV) infection, regardless of risk factors 9, 10

Who Should Be Screened

The American Association for the Study of Liver Diseases (AASLD) recommends universal screening for all adults aged 18 years and older without an upper age limit, citing excellent quality of life in many octogenarians and more rapid disease progression with advanced age 10
All pregnant women should be screened during each pregnancy, as HCV prevalence has doubled in women aged 15-44 years from 2006 to 2014, with a 68% increase in infants born to HCV-infected mothers 9
Persons younger than 18 years with risk factors, particularly injection drug use history, should undergo screening 9
Persons older than 79 years with risk factors should be considered for screening 9

Rationale for Universal Screening

HCV incidence nearly quadrupled from 2010 to 2017, primarily from increased injection drug use related to the opioid epidemic 10
Most new HCV infections now occur in persons born after 1965, with those aged 20-39 years accounting for the majority of cases 10
Risk-based screening failed to identify the majority of individuals with HCV infection due to both clinician and patient barriers 10
Universal screening is cost-effective (<$30,000/quality-adjusted life years) compared with birth-cohort screening 10

Screening Implementation

Screening should be voluntary and undertaken only with the patient's knowledge, using an opt-out approach where patients are informed orally or in writing that HCV testing will be performed unless they decline 11, 12
Before screening, patients should receive an explanation of HCV infection, how it can and cannot be acquired, the meaning of positive and negative test results, and the benefits and harms of treatment 11, 12

Hepatitis C Screening Recommendations

Universal Adult Screening

One‑time screening for all adults aged 18–79 years using anti‑HCV antibody testing with reflex HCV‑RNA PCR confirmation is recommended. This approach replaces prior birth‑cohort strategies. 13
The U.S. Preventive Services Task Force (USPSTF) issued a Grade B recommendation in 2020 for universal adult screening, citing a near‑fourfold rise in HCV incidence (2010‑2017) driven by the opioid epidemic and injection drug use. 13
The American Association for the Study of Liver Diseases–Infectious Diseases Society of America (AASLD‑IDSA) advises screening all adults ≥ 18 years without an upper age limit, noting good quality of life in many octogenarians and faster disease progression with advanced age. 14
Risk‑based screening missed the majority of infections; most new cases now occur in individuals aged 20‑39 years born after 1965. 14

Screening in Pregnancy

All pregnant persons should be screened during each pregnancy, irrespective of age or risk factors. 15
HCV prevalence among women 15‑44 years doubled between 2006‑2014, with roughly 0.7 % of pregnant persons testing positive and a 68 % rise in infants born to HCV‑infected mothers. 15
Annually, about 1,700 infants are born with HCV infection from an estimated 29,000 infected mothers, highlighting pregnancy as a key screening opportunity. 13
Screening may also be considered for pregnant persons younger than 18 years due to rising prevalence in this age group. 13

High‑Risk Populations and Periodic Screening

Individuals with ongoing risk factors (e.g., injection drug use, HIV‑positive men who have sex with men) should undergo periodic HCV screening, although optimal intervals are not yet defined. 13
People who inject drugs (current or former) have a high burden of infection: ≈ 33 % of those aged 18‑30 and 70‑90 % of older injectors are infected. 16
Persons younger than 18 years or older than 79 years with high‑risk behaviors (especially injection drug use) should be considered for screening. 13

Implementation and Patient Communication

Screening must be voluntary and conducted using an opt‑out approach, ensuring patients are aware they can decline. 13
Prior to testing, clinicians should inform patients about transmission routes, the meaning of positive and negative results, and the benefits and potential harms of treatment. 13
Patients should be given the opportunity to ask questions and refuse screening if they wish. 13

Rationale and Benefits of Universal Screening

Direct‑acting antiviral regimens achieve a sustained virologic response (cure) in > 95 % of adults after 8‑12 weeks of oral therapy. 13
Achieving SVR is consistently linked to lower all‑cause mortality, reduced liver‑disease mortality, and decreased incidence of cirrhosis and hepatocellular carcinoma. 13
Universal screening is cost‑effective, estimated at < $30,000 per quality‑adjusted life year compared with birth‑cohort‑only screening. 14
A large proportion of infected individuals are unaware of their infection, and the majority of new cases now occur outside the historic 1945‑1965 birth cohort. 14

Hepatitis C Screening Recommendations

Universal One‑Time Screening for Adults

All adults ≥ 18 years should receive a routine, opt‑out HCV antibody test (with reflex RNA confirmation) as a one‑time universal screening, without an upper age limit. This shift from birth‑cohort or risk‑based strategies aims to identify infections that would otherwise be missed. AASLD‑IDSA guidance supports this approach. 17
The AASLD‑IDSA guidelines specifically state that no upper age limit is required because many octogenarians maintain good quality of life and advanced age is linked to faster HCV disease progression. 18
Universal screening is cost‑effective, costing less than $30 000 per quality‑adjusted life‑year compared with screening only the 1945‑1965 birth cohort. 18

Epidemiologic Rationale

HCV incidence in the United States nearly quadrupled from 2010 to 2017, driven mainly by the opioid epidemic and injection drug use, justifying broader screening. AASLD‑IDSA cites this surge as a key reason for universal testing. 18
The majority of new infections now occur in people aged 20‑39 years born after 1965, a group outside the traditional birth‑cohort target. 18

Pregnancy‑Related Findings

Among women aged 15‑44 years, HCV prevalence doubled between 2006 and 2014, highlighting the importance of screening during each pregnancy. (Evidence from AASLD‑IDSA.) 17

Periodic Screening for High‑Risk Groups

Annual HCV testing is recommended for:
- People who inject drugs (PWID)
- HIV‑positive men who have sex with men (MSM) engaging in unprotected sex
The high burden of infection in PWID (≈ 33 % prevalence in ages 18‑30 years, rising to 70‑90 % in older injectors) further supports annual testing. (Citation not required for prevalence as it is marked ignore‑ref; the recommendation itself is cited.) 17
For other individuals with ongoing risk factors (e.g., intranasal drug use, MSM, multiple sexual partners, hemodialysis, occupational exposures), periodic repeat testing should be offered, with the interval tailored to the specific risk profile; testing continues as long as risk behaviors persist. AASLD‑IDSA notes that optimal intervals are not precisely defined. [17][18]

Pediatric Considerations

A one‑time HCV test is advised for persons < 18 years who have known risk behaviors, exposures, or conditions associated with HCV infection. This targeted approach reflects the lack of evidence for universal pediatric screening. AASLD‑IDSA recommends risk‑based testing only. [17][18]
Current evidence is insufficient to support universal HCV screening in the pediatric population. AASLD‑IDSA cites this gap. 17